These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 19042984)

  • 1. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
    Sturgeon CM; Duffy MJ; Stenman UH; Lilja H; Brünner N; Chan DW; Babaian R; Bast RC; Dowell B; Esteva FJ; Haglund C; Harbeck N; Hayes DF; Holten-Andersen M; Klee GG; Lamerz R; Looijenga LH; Molina R; Nielsen HJ; Rittenhouse H; Semjonow A; Shih IeM; Sibley P; Sölétormos G; Stephan C; Sokoll L; Hoffman BR; Diamandis EP;
    Clin Chem; 2008 Dec; 54(12):e11-79. PubMed ID: 19042984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum tumor markers.
    Perkins GL; Slater ED; Sanders GK; Prichard JG
    Am Fam Physician; 2003 Sep; 68(6):1075-82. PubMed ID: 14524394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers.
    Sturgeon CM; Duffy MJ; Hofmann BR; Lamerz R; Fritsche HA; Gaarenstroom K; Bonfrer J; Ecke TH; Grossman HB; Hayes P; Hoffmann RT; Lerner SP; Löhe F; Louhimo J; Sawczuk I; Taketa K; Diamandis EP;
    Clin Chem; 2010 Jun; 56(6):e1-48. PubMed ID: 20207771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor markers in clinical practice: a review focusing on common solid cancers.
    Duffy MJ
    Med Princ Pract; 2013; 22(1):4-11. PubMed ID: 22584792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor markers and nuclear medicine imaging modalities: breast, prostate and ovarian cancer.
    Ugrinska A; Bombardieri E; Stokkel MP; Crippa F; Pauwels EK
    Q J Nucl Med; 2002 Jun; 46(2):88-104. PubMed ID: 12114872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor markers in breast cancer- European Group on Tumor Markers recommendations.
    Molina R; Barak V; van Dalen A; Duffy MJ; Einarsson R; Gion M; Goike H; Lamerz R; Nap M; Sölétormos G; Stieber P
    Tumour Biol; 2005; 26(6):281-93. PubMed ID: 16254457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of common seric tumor markers in patients with solid cancers.
    Gara S; Boussen H; Ghanem A; Guemira F
    Tunis Med; 2008 Jun; 86(6):579-83. PubMed ID: 19216452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.
    Sölétormos G; Duffy MJ; Othman Abu Hassan S; Verheijen RH; Tholander B; Bast RC; Gaarenstroom KN; Sturgeon CM; Bonfrer JM; Petersen PH; Troonen H; CarloTorre G; Kanty Kulpa J; Tuxen MK; Molina R
    Int J Gynecol Cancer; 2016 Jan; 26(1):43-51. PubMed ID: 26588231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Significance of current bio- and molecular-markers in urological cancers].
    Shimazui T; Akaza H
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):1008-14. PubMed ID: 15272577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New tumor markers: CA125 and beyond.
    Bast RC; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly KA; Atkinson EN; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K
    Int J Gynecol Cancer; 2005; 15 Suppl 3():274-81. PubMed ID: 16343244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for the clinical use of tumour markers.
    Duffy MJ
    Ann Clin Biochem; 2004 Sep; 41(Pt 5):370-7. PubMed ID: 15333188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers.
    Kramer BS; Gohagan J; Prorok PC; Smart C
    Cancer; 1993 Jan; 71(2 Suppl):589-93. PubMed ID: 8420681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate specific antigen (PSA) in breast and ovarian cancer.
    Kucera E; Kainz C; Tempfer C; Zeillinger R; Koelbl H; Sliutz G
    Anticancer Res; 1997; 17(6D):4735-7. PubMed ID: 9494598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoparticle-aided glycovariant assays to bridge biomarker performance and ctDNA results.
    Gidwani K; Kekki H; Terävä J; Soukka T; Sundfeldt K; Pettersson K
    Mol Aspects Med; 2020 Apr; 72():100831. PubMed ID: 31787337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
    Chen C; Chen LQ; Yang GL; Li Y
    Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of tumor markers in patients with solid cancers: A critical review.
    Duffy MJ
    Eur J Intern Med; 2007 May; 18(3):175-84. PubMed ID: 17449388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overall and Multiphasic Findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) Randomized Cancer Screening Trial.
    Prorok PC; Wright P; Riley TR; Kramer BS; Berg CD; Gohagan JK
    Rev Recent Clin Trials; 2018; 13(4):257-273. PubMed ID: 29629665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical uses of tumor markers: a critical review.
    Duffy MJ
    Crit Rev Clin Lab Sci; 2001 Jun; 38(3):225-62. PubMed ID: 11451209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A personalized approach to cancer treatment: how biomarkers can help.
    Duffy MJ; Crown J
    Clin Chem; 2008 Nov; 54(11):1770-9. PubMed ID: 18801934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum mucin antigens CASA and MSA in tumors of the breast, ovary, lung, pancreas, bladder, colon, and prostate. A blind trial with 420 patients.
    Devine PL; McGuckin MA; Ramm LE; Ward BG; Pee D; Long S
    Cancer; 1993 Sep; 72(6):2007-15. PubMed ID: 7689923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.